Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Patients with Chronic HCV Infection.
Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease. Previously-available direct-acting antiviral (DAA) regimens are not approved for patients with advanced CKD across all HCV genotypes. EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4, or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status, and prior HCV treatment-experience. The primary efficacy endpoint was percentage of patients with sustained virologic response at 12 weeks post-treatment (SVR12). Among the 101 patients enrolled in the study, 24% had pre-dialysis CKD and 76% were on dialysis. 84 patients were treated with G/P for 8 weeks, 13 patients for 12 weeks, and 4 patients for 16 weeks. 55% of patients had genotype 1, 27% had genotype 2, 15% had genotype 3, and 4% had genotype 4, and none had genotype 5 or 6 infection. The SVR12 rate was 97% (98/101, 95% CI, 91.6-99.0). No patients experienced virologic failure. AEs reported in at least 5% of the patients were pruritus, bronchitis, hypertension, and generalized pruritus. Serious AEs were reported in 12% of patients; none related to study drug. G/P treatment yielded high SVR12 rates irrespective of the presence of stage 3b, 4 or 5 CKD. No safety signals were detected.